Showing papers in "Blood Reviews in 2017"

TL;DR: This review summarizes the most relevant molecular (genetic, epigenetic, and protein) biomarkers associated with acute myeloid leukemia and discusses their clinical importance in terms of risk prediction, diagnosis and prognosis.

TL;DR: Most ID patients are candidate to traditional treatment with oral iron salts, while high hepcidin levels block their absorption in inflammatory disorders, and high-dose intravenous iron compounds are becoming popular and indications to their use are increasing, although long-term side effects remain to be evaluated.

TL;DR: A critical review of VKAs and DOACs with focus on their potential for interactions with drugs, foods, herbs and over-the-counter medications is presented.

TL;DR: There is insufficient evidence available to date to strongly recommend for or against consolidative stem cell transplant in this population of high grade B-cell lymphomas with inferior outcomes when treated with standard RCHOP chemotherapy.

TL;DR: This review summarizes the discovery of five new FA genes and describes how these proteins integrate into the FA-BRCA pathway to maintain genome stability and critically prevent early-onset BMF and cancer.

TL;DR: The microanatomy of the BM is discussed and an overview of the evidence supporting the role of theBM microenvironment in creating conditions conducive to the survival and proliferation of AML blasts is provided.

TL;DR: Additional research is needed to better understand the effects of APLA on activation of signaling pathways in vascular cells, to identify more predictive biomarkers that define patients at greatest risk for a first or recurrent APLA-related clinical event, and to determine the safety and efficacy of DOACs and novel anti-inflammatory and immune-modulatory therapies for refractory APS.

TL;DR: Current knowledge about molecular mechanisms of leukemic T- cell infiltration with special emphasis on the newly identified subtype early T-cell-progenitor (ETP)-ALL is summarized and extravasation potential of T-ALL cells is compared with that of other hematologic malignancies such as B-ALL and acute myeloid leukemia (AML).

TL;DR: The utility of currently available assays for assessment of DOAC effect is reviewed and an optimal assessment strategy for each drug is recommended, including calibrated dilute thrombin time or ecarin-based assay for dabigatran and calibrated anti-Xa activity Assays for the factor Xa inhibitors.

TL;DR: This paper analyzes concurrent multiple predisposing factors that could favor the onset of fungal infections in patients with hematological malignancies undergoing conventional chemotherapy, autologous or allogeneic hematopoietic stem cell transplantation, and Aspergillus spp.

TL;DR: The molecular mechanisms dictating eryptosis and erythrophagocytosis are reviewed and the current evidence leading to the pathophysiological ramifications of eryPTotic cell death in the context of human disease is critically analyzed.

TL;DR: E enrolment into clinical trials of novel agents with varying mechanisms of action should be considered for all older adults with acute myeloid leukaemia.

TL;DR: The physiologic role of the NF-κB pathway and recent advances in better understanding of the pathologic roles are presented and an update of clinical trials that use NF-σB pathway inhibitors is provided.

TL;DR: The review will summarize present knowledge on mutant NPM1 origin, pathogenesis, and therapy in AML and outline the possible therapeutic interventions for the treatment of AML by targeting N PM1.

TL;DR: In this paper, a three-pronged strategy integrating different perspectives on the biological mechanisms underlying blood-biomaterial interactions is presented. But the success of this strategy depends on reengaging clinicians and on renewed cooperation of the funding agencies to support long-term efforts.

TL;DR: A potential contribution of IL-1β linking to complications and autoimmune disease that should be investigated in future studies is highlighted, and drugs that target IL- 1 may be helpful to improve outcome or reduce morbidity in patients.

TL;DR: The role of bone marrow evaluation and peripheral blood monitoring in the diagnosis, management, and follow up of AML patients is discussed.

TL;DR: The methodological principles of MRD assays are reviewed, the clinical implications of monitoring MRD for risk stratification and directing further therapy are discussed, and potential areas for future investigation are suggested.

TL;DR: The biological features of each of the components in the BCL-2 apoptotic pathways are summarized, the regulatory mechanisms and the pivotal roles of B CL-2 family members in the pathogenesis of major types of hematologic malignances are analyzed, and the potential of apoptosis- and Bcl-2-targeted strategies as effective approaches in anti-cancer therapies are evaluated.

TL;DR: Most patients were treated with F13 concentrates to arrest bleeding and with prednisolone and cyclophosphamide to eradicate anti-F13 autoantibodies, and physicians/hematologists must raise the awareness of AH13 as a life-threatening disease.

TL;DR: In healthy subjects and patients with hematological diseases, platelet populations can be distinguished with different response spectra in hemostatic and vascular processes, and in vivo and in vitro markers of platelet activation can differ in thrombotic and hematology disorders.

TL;DR: The clinical impact of CMV in the setting of alloHCT, interactions between CMV serostatus, viral reactivation, and transplant outcomes, as well as current and evolving strategies for prevention and treatment ofCMV-related complications that may have significant impact for allo HCT recipients are reviewed.

TL;DR: The role of mTOR inhibition in AML, mechanisms of resistance, and means to improve outcomes through use of dual mTORC1/2 inhibitors or dual TORC/PI3K inhibitors are explored.

TL;DR: This area of focus over the last 7years has been the reduction of ED in both academic and community centers and an effective strategy is to utilize a set of simplified treatment guidelines coupled with support from a group of experts during induction.

TL;DR: This review aims to provide haematologists with an overview of results from in vitro and murine models and preliminary clinical evidence on the diagnostic, prognostic and therapeutic implications of the complex interactions between the haemopoietic niche, iron, oxidative stress and inadequate haemipoiesis.

TL;DR: In this article, the authors used β-thalassemia as a paradigmatic example to describe current knowledge on the mechanisms leading to ineffective erythropoiesis and novel treatments that may have the potential to improve the clinical phenotype of associated diseases in the future.

TL;DR: Questions remain however, about this complex genetic disorder and how to incorporate emerging knowledge into diagnostic strategies about von Willebrand disease.

TL;DR: The p53 landscape in B-cell malignancies, from B-Acute Lymphoblastic Leukemia to Plasma Cell Leukemia, is described by analyzing incidence of gain or loss of function of actors both upstream and within the p53 pathway, namely MYC, RAS, ARF, MDM2, ATM and TP53.

TL;DR: This systematic review aimed to summarize current evidence on the safety and efficacy of clinical decision rules and biomarkers used in the diagnostic management of suspected acute PE in pregnant patients.

TL;DR: A systematic review of studies in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome that incorporated patient-reported outcome (PRO) measures and found well-implemented PROs can provide important information beyond objective response outcomes.